Cuvillier Verlag

35 Jahre Kompetenz im wissenschaftlichen Publizieren
Internationaler Fachverlag für Wissenschaft und Wirtschaft

Cuvillier Verlag

De En Es
Systems metabolic engineering  of Escherichia coli for production of violacein and deoxyviolacein

EUR 28,50

EUR 19,90

Systems metabolic engineering of Escherichia coli for production of violacein and deoxyviolacein (Band 4)

André Luis Rodrigues (Autor)


Inhaltsverzeichnis, PDF (57 KB)
Leseprobe, PDF (210 KB)

ISBN-13 (Printausgabe) 9783954049608
ISBN-13 (E-Book) 9783736949607
Sprache Englisch
Seitenanzahl 128
Umschlagkaschierung matt
Auflage 1. Aufl.
Buchreihe Hochschulschriften - Institut für Systembiotechnologie, Universität des Saarlandes
Band 4
Erscheinungsort Göttingen
Erscheinungsdatum 13.07.2015
Allgemeine Einordnung Dissertation
Fachbereiche Mikrobiologie und Biotechnologie
Schlagwörter violacein, deoxyviolacein, Escherichia coli, metabolic engineering

Violacein and deoxyviolacein are promising therapeutics against pathogenic bacteria and viruses as well as tumor cells. In the present work, systems-wide metabolic engineering was applied to Escherichia coli for heterologous production of these high-value products. First, a high performance liquid chromatography method for accurate separation and quantification of violacein and deoxyviolacein was developed. Afterwards, a basic producer, E. coli dVio-1, that expressed the vioABCE cluster from Chromobacterium violaceum under control of the araBAD promoter and induction by L-arabinose, was constructed. Targeted intracellular metabolite analysis then identified bottlenecks in pathways that supply tryptophan, the major product building block of the natural products of interest. This was used for systems-wide engineering of serine, chorismate and tryptophan biosynthesis and the non-oxidative pentose-phosphate pathway, followed by elimination of L-arabinose catabolism. Transferred to a glycerol-based fed-batch process, E. coli dVio-8 surpassed the gram scale and produced 1.6 g L-1 deoxyviolacein (> 99.5% purity). The created chassis of a high-flux tryptophan pathway was complemented by genomic integration of the vioD gene of Janthinobacterium lividum, which enabled exclusive production of violacein (710 mg L-1 with 99.8% purity). This demonstrates the potential of E. coli as a platform for production of tryptophan based therapeutics.